Slide
Centre Interdisciplinaire
de Recherche et d’Innovation
en Cybersécurité et Société
de Recherche et d’Innovation
en Cybersécurité et Société
1.
Fernández-Álvarez, J.; Rozental, A.; Carlbring, P.; Colombo, D.; Riva, G.; Anderson, P. L.; Baños, R. M.; Benbow, A. A.; Bouchard, S.; Bretón-López, J. M.; Cárdenas, G.; Difede, J.; Emmelkamp, P.; García-Palacios, A.; Guillén, V.; Hoffman, H.; Kampann, I.; Moldovan, R.; Mühlberger, A.; North, M.; Pauli, P.; Castro, W. Peñate; Quero, S.; Tortella-Feliu, M.; Wyka, K.; Botella, C.
Deterioration rates in Virtual Reality Therapy: An individual patient data level meta-analysis Article de journal
Dans: Journal of Anxiety Disorders, vol. 61, p. 3–17, 2019, ISSN: 08876185 (ISSN), (Publisher: Elsevier Ltd).
Résumé | Liens | BibTeX | Étiquettes: Adolescent, adult, aged, Anxiety disorder, Anxiety Disorders, article, demography, deterioration, Deterioration rates, disease association, female, human, Humans, Individual patient data analysis, male, marriage, meta analysis, Middle Aged, Odds Ratio, outcome assessment, Probability, psychology, randomized controlled trial (topic), social status, virtual reality, virtual reality exposure therapy, Young Adult
@article{fernandez-alvarez_deterioration_2019,
title = {Deterioration rates in Virtual Reality Therapy: An individual patient data level meta-analysis},
author = {J. Fernández-Álvarez and A. Rozental and P. Carlbring and D. Colombo and G. Riva and P. L. Anderson and R. M. Baños and A. A. Benbow and S. Bouchard and J. M. Bretón-López and G. Cárdenas and J. Difede and P. Emmelkamp and A. García-Palacios and V. Guillén and H. Hoffman and I. Kampann and R. Moldovan and A. Mühlberger and M. North and P. Pauli and W. Peñate Castro and S. Quero and M. Tortella-Feliu and K. Wyka and C. Botella},
url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-85050381788&doi=10.1016%2fj.janxdis.2018.06.005&partnerID=40&md5=012fdcaa9b8676314cbf22c52c91135b},
doi = {10.1016/j.janxdis.2018.06.005},
issn = {08876185 (ISSN)},
year = {2019},
date = {2019-01-01},
journal = {Journal of Anxiety Disorders},
volume = {61},
pages = {3–17},
abstract = {Ample evidence supports the use of Virtual Reality (VR) for anxiety disorders. Nonetheless, currently there is no evidence about moderators or potential negative effects of VR treatment strategies. An Individual Patient Data (IPD) approach was employed with 15 retrieved datasets. The current study sample was composed of 810 patients. Randomized control trials (RCTs) for each primary outcome measure were performed, in addition to moderator analyses of the socio-demographic variables. Deterioration rates were 14 patients (4.0%) in VR, 8 (2.8%) in active control conditions, and 27 (15%) in the WL condition. With regard to receiving treatment, patients in a waiting list control condition had greater odds of deteriorating than in the two active conditions, odds ratios (ORs) 4.87, 95% confidence interval (CI) [0.05, 0.67]. In the case of the socio-demographic variables, none of them were associated with higher or lower odds of deterioration, with the exception of marital status in the WL condition; married people presented a significantly lower probability of deterioration, OR 0.19, 95% CI [0.05, 0.67]. Finally, when comparing pooled effects of VR versus all control conditions, the OR was 0.61 (95% CI 0.31–1.23) in favor of VR, although this result was not statistically significant. This study provides evidence about the deterioration rates of a therapeutic VR approach, showing that the number of deteriorated patients coincides with other therapeutic approaches, and that deterioration is less likely to occur, compared to patients in WL control groups. © 2018 Elsevier Ltd},
note = {Publisher: Elsevier Ltd},
keywords = {Adolescent, adult, aged, Anxiety disorder, Anxiety Disorders, article, demography, deterioration, Deterioration rates, disease association, female, human, Humans, Individual patient data analysis, male, marriage, meta analysis, Middle Aged, Odds Ratio, outcome assessment, Probability, psychology, randomized controlled trial (topic), social status, virtual reality, virtual reality exposure therapy, Young Adult},
pubstate = {published},
tppubtype = {article}
}
Ample evidence supports the use of Virtual Reality (VR) for anxiety disorders. Nonetheless, currently there is no evidence about moderators or potential negative effects of VR treatment strategies. An Individual Patient Data (IPD) approach was employed with 15 retrieved datasets. The current study sample was composed of 810 patients. Randomized control trials (RCTs) for each primary outcome measure were performed, in addition to moderator analyses of the socio-demographic variables. Deterioration rates were 14 patients (4.0%) in VR, 8 (2.8%) in active control conditions, and 27 (15%) in the WL condition. With regard to receiving treatment, patients in a waiting list control condition had greater odds of deteriorating than in the two active conditions, odds ratios (ORs) 4.87, 95% confidence interval (CI) [0.05, 0.67]. In the case of the socio-demographic variables, none of them were associated with higher or lower odds of deterioration, with the exception of marital status in the WL condition; married people presented a significantly lower probability of deterioration, OR 0.19, 95% CI [0.05, 0.67]. Finally, when comparing pooled effects of VR versus all control conditions, the OR was 0.61 (95% CI 0.31–1.23) in favor of VR, although this result was not statistically significant. This study provides evidence about the deterioration rates of a therapeutic VR approach, showing that the number of deteriorated patients coincides with other therapeutic approaches, and that deterioration is less likely to occur, compared to patients in WL control groups. © 2018 Elsevier Ltd
2.
Savard, J.; Laberge, B.; Gauthier, J. G.; Founder, J. -P.; Bouchard, S.; Baril, J. -G.; Bergeron, M. G.
Combination of fluoxetine and cognitive therapy for the treatment of major depression among people with HIV infection: A time-series analysis investigation Article de journal
Dans: Cognitive Therapy and Research, vol. 22, no 1, p. 21–46, 1998, ISSN: 01475916 (ISSN), (Publisher: Springer New York LLC).
Résumé | Liens | BibTeX | Étiquettes: adult, AIDS, alcoholism, article, clinical article, clinical trial, clonazepam, cognitive therapy, comorbidity, demography, Depression, disease association, drug efficacy, female, fluoxetine, HIV, human, Human immunodeficiency virus infection, male, patient attitude, personality disorder, relapse, Treatment, treatment outcome
@article{savard_combination_1998,
title = {Combination of fluoxetine and cognitive therapy for the treatment of major depression among people with HIV infection: A time-series analysis investigation},
author = {J. Savard and B. Laberge and J. G. Gauthier and J. -P. Founder and S. Bouchard and J. -G. Baril and M. G. Bergeron},
url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-0031957952&doi=10.1023%2fA%3a1018759802082&partnerID=40&md5=bf7c480d95e52b00202cfcb1f34af74f},
doi = {10.1023/A:1018759802082},
issn = {01475916 (ISSN)},
year = {1998},
date = {1998-01-01},
journal = {Cognitive Therapy and Research},
volume = {22},
number = {1},
pages = {21–46},
abstract = {The aim of the present study was to evaluate the efficacy of a combined treatment of fluoxetine and cognitive therapy for the treatment of major depression in HIV-infected patients. Six HIV-seropositive patients with major depression participated in this study using a multiple-baseline experimental design with follow-up and direct replications. Results of time-series intervention analyses suggest that the combination of fluoxetine and cognitive therapy can provide an effective treatment for major depression in HIV illness that may be more effective than fluoxetine alone. However, relapse rates and follow-up results raise some concerns about the long-term efficacy of the combined treatment as administered in this study. Cooccurence of a personality disorder is suggested as an explanatory hypothesis.},
note = {Publisher: Springer New York LLC},
keywords = {adult, AIDS, alcoholism, article, clinical article, clinical trial, clonazepam, cognitive therapy, comorbidity, demography, Depression, disease association, drug efficacy, female, fluoxetine, HIV, human, Human immunodeficiency virus infection, male, patient attitude, personality disorder, relapse, Treatment, treatment outcome},
pubstate = {published},
tppubtype = {article}
}
The aim of the present study was to evaluate the efficacy of a combined treatment of fluoxetine and cognitive therapy for the treatment of major depression in HIV-infected patients. Six HIV-seropositive patients with major depression participated in this study using a multiple-baseline experimental design with follow-up and direct replications. Results of time-series intervention analyses suggest that the combination of fluoxetine and cognitive therapy can provide an effective treatment for major depression in HIV illness that may be more effective than fluoxetine alone. However, relapse rates and follow-up results raise some concerns about the long-term efficacy of the combined treatment as administered in this study. Cooccurence of a personality disorder is suggested as an explanatory hypothesis.